focus -WSS

focus

author：entertainment 2025-10-01 12:10:43 - browse：73695

Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Supreme Court strikes down use of affirmative action
Next article： Glen Campbell's doctor discusses his public struggle with Alzheimer's

WSS

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Second House panel advances two

Vertex non

Addiction experts warn against a second 'war on drugs'

FTC sues over Novant Health acquisition of two N.C. hospitals

focus

focus

explore

Activists slam private health insurers over coverage restrictions

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The high cost of giving birth even with insurance

NVIDIA and Google execs on the future of AI and drug discovery

Jerome Adams on the need for new antivirals for Covid

Merck, Johnson & Johnson CEOs will testify on high drug prices

Supreme Court strikes down use of affirmative action

It's time to retire 'poor historian' from clinicians' vocabularies

explore

With measles on the rise, a personal story of a devastating disease

Medicare Advantage insurers face 0.2% cut to 2025 payments

Why Medicare shouldn’t cover every FDA

Data integrity in scientific journals requires "effort" by publishers, institutions

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Boston competes with Raleigh

hotspot

hotspot

leisure time

focus